News Detail - Eckert & Ziegler Strahlen- und Medizintechnik AG

Eckert & Ziegler with special income of EUR 7.3 million


ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Quarter Results
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 5 May 2008 – In the first quarter of 2008, Eckert & Ziegler Strahlen und Medizintechnik AG (ISIN DE 0005659700) will record extraordinary earnings amounting to EUR 7.3 million or EUR 2.34 per share. This can be attributed to the sale of the business with prostate cancer implants to the Belgian company International Brachytherapy SA in February and results from the difference between an extraordinary book profit amounting to EUR 14 million on the one hand and a series of related special amortizations and provisions amounting to EUR 6.7 million which the Executive Board of the Berlin company decided on at its meeting today.
As well as this special income, in the first quarter the isotope specialist from Pankow will also record a profit of EUR 0.6 million or EUR 0.19 per share arising from operational business, so a total of EUR 8 million or EUR 2.53 per share. Further details about the special income and the figures for the first quarter will be published with the I/2008 quarterly report on 6 May 2008 and one of the places where they can be viewed is on the company website www.ezag.de. Andreas Eckert, CEO of Eckert & Ziegler AG, is available to answer further questions in a telephone conference, held on 6 May 2008 at 10.15 a.m.

The Executive Board


Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 94 10 84-139, Fax -112, E-mail: thomas.scheuch@ezag.de, www.ezag.de



05.05.2008  Financial News transmitted by DGAP

 
Language:     English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG               Robert-Rössle-Str. 10
              13125 Berlin
              Deutschland
Phone:        +49 (0)30 941 084-0
Fax:          +49 (0)30 941 084-112
E-mail:       thomas.scheuch@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700
WKN:          565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Hamburg, Düsseldorf  
End of News DGAP News-Service